Session Information
Date: Monday, October 8, 2018
Session Title: Parkinson's Disease: Genetics
Session Time: 1:15pm-2:45pm
Location: Hall 3FG
Objective: Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than 7 million people worldwide. However, treatment outcome in many patients with Parkinson’s disease is inadequate or poor. Patients may be unresponsive or only partially responsive to treatment, they may suffer adverse and even toxic effects of drugs, and anti Parkinson’s drugs may interact with other medication. These may all be factors that additionally contribute to negative treatment results, frequent relapses, poorer quality of life, and of course, to higher treatment costs. TDM may provide a rational basis for optimal drug therapy and a suitable tool for accurately assessing the drug-related phenotype.
Background: Integration of information about a patient’s phenotype and genotype provides a rational basis for drug and dose selection, and for dose regimen for many anti Parkinson’s drugs in clinical practice.
Methods: An algorithm on the use of TDM and pharmacogenetic tests to help characterise adverse drug reactions.
Results: Cost-effectiveness for the use of newer anti Parkinson’s drug in the elderly has been proven since the implementation of TDM reduced direct costs by 10 %.
Conclusions: With the aim of treatment optimization, certain phenotypic genetic biomarkers undoubtedly play an important role in the recognition of treatment-responsive and unresponsive patients, and they reduce the risk of drug toxicity by enabling individual dosage adjustment. TDM and pharmacogenetic testing both may improve acute and long-term treatment, prediction of therapeutic response, possible correlations with treatment outcome, and monitoring of treatment compliance and can represent a prominent step towards creative anti Parkinson’s therapy.
References: Lertxundi U et. all (2015) Clin Neuropharmacol.38(3):69-84. doi: 10.1097/WNF.0000000000000080.
To cite this abstract in AMA style:
N. Verma. Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance of Anti Parkinson’s Therapy [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/therapeutic-drug-monitoring-and-pharmacogenetic-tests-as-tools-in-pharmacovigilance-of-anti-parkinsons-therapy/. Accessed June 14, 2025.« Back to 2018 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/therapeutic-drug-monitoring-and-pharmacogenetic-tests-as-tools-in-pharmacovigilance-of-anti-parkinsons-therapy/